Frequently Question Asked
The global OTC cough cold and allergy medicine market was valued at USD 37.2 Billion in 2022.
The OTC cough cold and allergy medicine market is expected to grow at a CAGR of 5.2% between 2023 and 2030, reaching USD 53.0 Billion in 2030.
Online is the leading segment by Application, holding over 75% share in value in 2022.
Antihistamines segment governs the global demand for OTC cough cold and allergy medicine, holding a massive share of over 30% in 2022.
The antibiotics segment is expected to post the highest CAGR during the forecast period.
North America is fueling the growth of the OTC cough cold and allergy medicine industry, with an over one-third share in 2022.
The top players include Sanofi-Aventis, Johnson and Johnson, Reckitt Benckiser Group, Novartis, GlaxoSmithKline, and AstraZaneca.
The major market drivers are the increasing prevalence of respiratory conditions, shifting consumer behavior and preference for self-care, and growing demand for natural and herbal remedies.
The major market restraints are strict regulatory requirements, compliance standards, safety concerns, and potential side effects.
Growing demand for natural and herbal remedies, expanding elderly population and age-related respiratory issues, and increasing disposable incomes in emerging markets.